After several years of collaboration, Professor Dr Dean Lee has become a formal member of the scientific advisory board of CiMaas as of December 18, 2022.
CiMaas BV, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary NK cell expansion platform, announced the date for a presentation of the company at the Biotech Showcase 2023, the investor conference as follows: Monday, January 09, 2023, at 3:00PM at the Hilton San Francisco – Union Square, 333 O’Farrell… Read more »
CiMaas successfully expands Natural Killer (NK) cells to clinically relevant numbers using a 2-week protocol. Starting from 200 ml peripheral blood, NK are expanded to numbers meeting the expected clinically required 10.E8 cells/kg, with multiple infusions. This makes the expansion method developed directly applicable for clinical application of the produced NK cells in anti-cancer therapies.
As of March 1, 2022, CiMaas is a licensed manufacturer for cell-based products. The company received the manufacturing authorization from the Dutch Ministry of Health, Welfare and Sport – Farmatec/CIBG.
CiMaas, together with the Maastricht University Medical Center+ and the University Medical Center Utrecht have received a subsidy of € 1,48 million to further develop Natural Killer Cell therapy for breast cancer.
Cimaas has received an important stimulus from the Netherlands Enterprise Agency (RVO) for the development of a therapeutic dendritic cell (DC) vaccine against lung cancer. It concerns a loan of € 2.4 million.
As of October 1, 2020 esteemed tumor immunologist Prof Dr Jolanda de Vries becomes a member of the scientific advisory board. Jolanda de Vries is head of the department of Tumor Immunology at Radboudumc, Nijmegen, the Netherlands.
Dutch website Oncologie.nu has interviewed CiMaas’ Gerard Bos on the development of the dendritic cell vaccine for lung cancer.
While CiMaas is able to produce the required high numbers of natural killer (NK) cells intended to realise in the collaboration, we decided not to continue. Kiadis has refocused its clinical strategy to a concept of universal donors while CiMaas keeps working on the process of individual donors for each cancer patient where NK cells… Read more »
CiMaas CEO Prof Gerard Bos was interviewed about the current and future directions for dendritic cell vaccines.